News
Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...
Zacks.com on MSN46m
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data
LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback